Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Samol, J Ranson, Malcolm R Scott, E Macpherson, E Carmichael, J Thomas, A Cassidy, J
Samol, J
Ranson, Malcolm R
Scott, E
Macpherson, E
Carmichael, J
Thomas, A
Cassidy, J
Citations
Altmetric:
Abstract
The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered olaparib (AZD2281) in combination with topotecan in patients with advanced solid tumors.
Affiliation
Description
Date
2012-08
Publisher
Collections
Keywords
Type
Article
Citation
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. 2012, 30 (4):1493-500 Invest New Drugs